XASX
IMR
Market cap340mUSD
Oct 30, Last price
1.35AUD
1D
3.85%
1Q
-27.42%
IPO
9.76%
Name
Imricor Medical Systems Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Key people
Steve Wedan
Executive Chairman of the Board, President, Chief Executive Officer · since 2006
Mark Tibbles
Non-Executive Lead Independent Deputy Chairman of the Board · since 2014
Jonathon Gut
Chief Financial Officer, Vice President - Finance · since 2022
Gregg Stenzel
Chief Operating Officer · since 2021
Vic Fabano
Vice President - Operations · since 2022
Nick Corkill
Vice President - Corporate Strategy · since 2024
Dan Sunnarborg
Vice President - Engineering · since 2007
Jennifer Weisz
Vice President - Regulatory and Quality · since 2018
Greg Englehardt
Executive Director of Sales · since 2018
Nick Twohy
Vice President of Marketing · since 2019
Kate Lindborg
Director of Clinical Affairs · since 2022
Kobe Li
Company Secretary · since 2019
Jeffrey Leighton
Director · since 2024
Peter Mcgregor
Non-Executive Director · since 2019
Non-Executive Independent Director · since 2025
Anita Messal
Non-Executive Independent Director · since 2021
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||